AN2 Therapeutics (ANTX)

• Market cap: $40.6M
• 1 day: -2.86%
• 5 days: 1.49%
• 1 month: -2.16%
• 3 months: 30.77%
• 6 months: -34.30%
• Year to date: -93.16%
• 1 year: -93.47%
• 5 years: -91.17%
• 10 years: -91.17%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Employees: 36

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

20.19% less ownership

Funds ownership: 65.48% [Q2] → 45.29% (-20.19%) [Q3]

30% less funds holding

Funds holding: 46 [Q2] → 32 (-14) [Q3]

61% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 23

66% less capital invested

Capital invested by funds: $42M [Q2] → $14.5M (-$27.5M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 268% upside
• Avg. target: $5 268% upside
• High target: $5 268% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Roy Buchanan 13% 1-year accuracy 2 / 16 met price target

268% upside $5

Market Outperform Reiterated

19 Nov 2024